Evidence map›Paper›PMID 31741193›Full record

ArticleStem cell reviews and reports2019

Wharton's Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: a Close-up on Immunomodulatory Molecules Featured In Situ and In Vitro.

Tiziana Corsello, Giandomenico Amico, Simona Corrao, Rita Anzalone, Francesca Timoneri, Melania Lo Iacono, Eleonora Russo, Giovanni Francesco Spatola, Maria Laura Uzzo, Mario Giuffrè and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Stem cell reviews and reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. State of the Art: The Immunomodulatory Role of MSCs for Osteoarthritis.International journal of molecular sciences · 2022
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 4 countries.

Tiziana CorselloUnit of Histology and Embryology, Department of Biomedicine Neurosciences and Advanced Diagnostics (BiND), University of Palermo, Via del Vespro 129, 90127, Palermo, PA, Italy.
Giandomenico AmicoRi.MED Foundation, Palermo, Italy.
Simona CorraoUnit of Histology and Embryology, Department of Biomedicine Neurosciences and Advanced Diagnostics (BiND), University of Palermo, Via del Vespro 129, 90127, Palermo, PA, Italy.
Rita AnzaloneDepartment of Surgical, Oncological and Stomatological Sciences (DICHIRONS), University of Palermo, Via del Vespro 129, 90127, Palermo, PA, Italy. rita.anzalone@unipa.it.
Francesca TimoneriRi.MED Foundation, Palermo, Italy.
Melania Lo IaconoCampus of Hematology F. and P. Cutino, Villa Sofia-Cervello Hospital, Palermo, Italy.
Eleonora RussoUnit of Histology and Embryology, Department of Biomedicine Neurosciences and Advanced Diagnostics (BiND), University of Palermo, Via del Vespro 129, 90127, Palermo, PA, Italy.
Giovanni Francesco SpatolaUnit of Histology and Embryology, Department of Biomedicine Neurosciences and Advanced Diagnostics (BiND), University of Palermo, Via del Vespro 129, 90127, Palermo, PA, Italy.
Maria Laura UzzoUnit of Histology and Embryology, Department of Biomedicine Neurosciences and Advanced Diagnostics (BiND), University of Palermo, Via del Vespro 129, 90127, Palermo, PA, Italy.
Mario GiuffrèDepartment PROMISE, University of Palermo, Palermo, Italy.
Martin Caprnda2nd Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia.
Peter KubatkaDepartment of Biology, Jessenius Faculty of Medicine in Martin, Martin, Slovakia.
Peter KruzliakDepartment of Internal Medicine, Brothers of Mercy Hospital, Brno, Czech Republic.
Pier Giulio ConaldiDepartment of Research, IRCCS ISMETT, Mediterranean Institute for Transplantation and Advanced Specialized Therapies, Palermo, Italy.
Giampiero La RoccaUnit of Histology and Embryology, Department of Biomedicine Neurosciences and Advanced Diagnostics (BiND), University of Palermo, Via del Vespro 129, 90127, Palermo, PA, Italy. giampylr@hotmail.com.ORCID 0000-0002-1334-5054
University of Palermo · ITRi.MED · ITIstituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione · ITMartin University Hospital · SKMasaryk University · CZOspedale Vincenzo Cervello · ITThe University of Texas Medical Branch at Galveston · USUniversity Hospital Bratislava · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic options for end-stage organ failure are often limited to whole organ transplantation. The tolerance or rejection of the transplanted organ is driven by both early non-specific innate and specific adaptive responses. The use of mesenchymal stromal cells (MSCs) is considered a promising tool in regenerative medicine. Human umbilical cord (HUC) is an easily available source of MSCs, without relevant ethical issues. Moreover, Wharton's jelly-derived MSCs (WJ-MSCs), showed consistent immunomodulatory features that may be useful to promote immune tolerance in the host after transplantation. Few data are available on the phenotype of WJ-MSCs in situ. We investigated the expression of immune-related molecules, such as HLAs, IDO, CD276/B7-H3, and others, both in situ (HUC) and in in vitro-cultured WJ-MSCs. Morphological and biochemical techniques were used to define the expression of such molecules. In addition, we focused on the possible role of CD276/B7-H3 on T cells proliferation inhibition. We assessed CD276/B7-H3 expression by WJ-MSCs both in situ and alongside cell culture. WJ-MSCs were able to suppress T cell proliferation in mixed lymphocyte reaction (MLR). Moreover, we describe for the first time a specific role for CD276/B7-H3, since the immunomodulatory ability of WJ-MSCs was abolished upon anti-CD276/B7-H3 antibody addition to the MLR. These results further detail the immune regulation properties and tolerance induction exerted by human WJ-MSCs, in particular pointing to CD276/B7-H3 as one of the main involved factors. These data further suggest WJ-MSCs as potent tools to modulate local immune response in "support-type" regenerative medicine approaches.

Indexed as

Cell DifferentiationB7 AntigensCell ProliferationCells, CulturedCytokinesHumansIn Vitro TechniquesLymphocyte ActivationMesenchymal Stem CellsUmbilical CordWharton JellyB7 AntigensCD276 protein, humanCytokinesB7-H3CD276Cell therapyHuman umbilical cordImmunomodulationLymphocyte inhibitionRegenerative medicineStem cellsWharton’s jelly mesenchymal stromal cells

Identifiers

PMID31741193
OpenAlexW2984610795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.